Biswas Sagnik, Gupta Sanchita, Mehta Shubham, Swaroop Shekhar, Aggarwal Arnav, Agarwal Ayush, Saxena Sarthak, Sehgal Tushar, Aggarwal Samagra, Gunjan Deepak, Nayak Baibaswata, Gamanagatti Shivanand
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India.
Department of Radiodiagnosis and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India.
J Clin Exp Hepatol. 2025 May-Jun;15(3):102467. doi: 10.1016/j.jceh.2024.102467. Epub 2024 Nov 30.
There are limited studies assessing whether prophylactic platelet transfusions prior to high-risk procedures reduce the risk of bleeding in patients with liver cirrhosis.
We performed a analysis of two prior randomized clinical trials (CTRI/2017/12/010822 and CTRI/2021/05/033464), which compared thromboelastography-guided prophylactic platelet transfusion to standard-of-care (empirical prophylactic transfusion for all patients prior to the procedure) or on-demand transfusion (no prophylactic transfusions). We aimed to assess the risk of major procedure-related bleeding or mortality among patients who had received prophylactic platelet transfusions versus those who did not (on-demand transfusions).
A total of 118 patients were included in the analysis, with baseline demographics well matched between groups. The leading etiologies of cirrhosis were cryptogenic (42, 35.6%) and autoimmune liver disease (30, 25.4%). The most common procedures performed were percutaneous liver biopsy (73, 61.8%), followed by transjugular intrahepatic portosystemic shunt (14, 11.9%) and transarterial chemoembolization (14, 11.9%). No episode of major bleeding or procedure-related mortality occurred in either group, though minor bleeding occurred in 5 patients. A significantly lower number of patients in the on-demand group required platelet transfusions than those receiving empirical transfusions as part of standard care.
Procedure-related bleeding rates were not significantly higher among patients with liver cirrhosis undergoing high-risk procedures without prophylactic platelet transfusions than in those who received them. Larger randomized trials are required to validate these findings from our analysis.
评估高风险手术前预防性输注血小板是否能降低肝硬化患者出血风险的研究有限。
我们对两项既往的随机临床试验(CTRI/2017/12/010822和CTRI/2021/05/033464)进行了荟萃分析,这两项试验比较了血栓弹力图引导的预防性血小板输注与标准治疗(手术前对所有患者进行经验性预防性输血)或按需输血(不进行预防性输血)。我们旨在评估接受预防性血小板输注的患者与未接受预防性血小板输注的患者(按需输血)相比,发生重大手术相关出血或死亡的风险。
共有118例患者纳入分析,两组的基线人口统计学特征匹配良好。肝硬化的主要病因是隐源性(42例,35.6%)和自身免疫性肝病(30例,25.4%)。最常见的手术是经皮肝活检(73例,61.8%),其次是经颈静脉肝内门体分流术(14例,11.9%)和经动脉化疗栓塞术(14例,11.9%)。两组均未发生重大出血或手术相关死亡事件,不过有5例患者发生了轻微出血。按需输血组需要输注血小板的患者数量明显低于接受经验性输血作为标准治疗一部分的患者。
在接受高风险手术的肝硬化患者中,未进行预防性血小板输注的患者与接受预防性血小板输注的患者相比,手术相关出血率并无显著更高。需要更大规模的随机试验来验证我们荟萃分析的这些结果。